Skip to main content
OpenTrials

Clinical trial condition

Immunoglobulin Light-chain Amyloidosis

Explore clinical trials studying Immunoglobulin Light-chain Amyloidosis. Study availability and eligibility vary by location and protocol.

182 public trials 42 recruiting studies
Refine in advanced search Browse all conditions

Immunoglobulin Light-chain Amyloidosis trial results

Active, Not Recruiting

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

NCT04754945

Conditions
AL Amyloidosis, Amyloidosis, Immune System Diseases, +10 more
Locations
  • University of California Orange, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
View Trial Details
Active, Not Recruiting

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

NCT06097832

Conditions
Amyloidosis, Immune System Diseases, Immunoglobulin Light-chain Amyloidosis, +10 more
Locations
  • Sutter Health Alta Bates Berkeley, California, United States
  • City of Hope Duarte, California, United States
  • University of California Los Angeles Los Angeles, California, United States
  • University of California Davis Medical Center Sacramento, California, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

NCT05451771

Conditions
AL Amyloidosis, Amyloidosis, Immune System Diseases, +10 more
Locations
  • Boston Medical Center Boston, Massachusetts, United States
  • Mayo Clinic Rochester Rochester, Minnesota, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • New York Presbyterian Hospital/Columbia University Irving Medical Center New York, United States
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825

Conditions
AL Amyloidosis, Amyloidosis, Blood Protein Disorders, +13 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site San Francisco, California, United States
  • Research Site Weston, Florida, United States
View all 90 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235

Conditions
AL Amyloidosis, Amyloidosis, Blood Protein Disorders, +13 more
Locations
  • Research Site Scottsdale, Arizona, United States
  • Research Site Duarte, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site San Francisco, California, United States
View all 110 locations
View Trial Details
Active, Not Recruiting

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

NCT04847453

Conditions
Amyloidosis, Immune System Diseases, Immunoglobulin Light-chain Amyloidosis, +11 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

A Study of AT-02 in Subjects With Systemic Amyloidosis.

NCT05951049

Conditions
Amyloidosis, Amyloidosis; Systemic, Immune System Diseases, +10 more
Locations
  • Kansas City Kansas City, Kansas, United States
  • Cleveland Clinic Cleveland, Ohio, United States
  • OHSU (Oregon Health & Science University) Portland, Oregon, United States
  • Penn Presbyterian Medical Center Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT04270175

Conditions
AL Amyloidosis, Alzheimer Disease, Amyloid, +21 more
Locations
  • Stanford University Palo Alto, California, United States
  • Boston University Medical Center Boston, Massachusetts, United States
  • Weill Cornell Medicine - Multiple Myeloma Center New York, United States
  • Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details

Related conditions